- 2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F420)-Dependent Nitroreductase (Ddn)
-
Swapping the substituents in positions 2 and 4 of the previously synthesized but yet undisclosed 5-cyano-4-(methylthio)-2-arylpyrimidin-6-ones 4, ring closure, and further optimization led to the identification of the potent antitubercular 2-thio-substituted quinazolinone 26. Structure-activity relationship (SAR) studies indicated a crucial role for both meta-nitro substituents for antitubercular activity, while the introduction of polar substituents on the quinazolinone core allowed reduction of bovine serum albumin (BSA) binding (63c, 63d). While most of the tested quinazolinones exhibited no cytotoxicity against MRC-5, the most potent compound 26 was found to be mutagenic via the Ames test. This analogue exhibited moderate inhibitory potency against Mycobacterium tuberculosis thymidylate kinase, the target of the 3-cyanopyridones that lies at the basis of the current analogues, indicating that the whole-cell antimycobacterial activity of the present S-substituted thioquinazolinones is likely due to modulation of alternative or additional targets. Diminished antimycobacterial activity was observed against mutants affected in cofactor F420 biosynthesis (fbiC), cofactor reduction (fgd), or deazaflavin-dependent nitroreductase activity (rv3547), indicating that reductive activation of the 3,5-dinitrobenzyl analogues is key to antimycobacterial activity.
- Jian, Yanlin,Forbes, He Eun,Hulpia, Fabian,Risseeuw, Martijn D. P.,Caljon, Guy,Munier-Lehmann, Hélène,Boshoff, Helena I. M.,Van Calenbergh, Serge
-
p. 440 - 457
(2021/01/14)
-
- Synthesis of novel quinazolinone derivatives with methyl (E)-2-(3-methoxy)acrylate moiety
-
A new series of quinazolinone derivatives with methyl (E)-2-(3-methoxy) acrylate moiety have been designed and synthesized. All target compounds had been identified by 1H NMR spectrum, IR spectrum and HR-MS (high resolution mass spectrum). Three target compounds (10a, 10e, 10h) were chosen to preliminarily test the antibacterial activities, the results showed that all three target compounds exhibited antibacterial activities against three bacterial strains (Proteobacteria, Salmonella, Colibacillus).
- Dong, Kui-Kui,Zhou, Hua-Hong,Guo, A-Rong,Chen, Tian,Wang, Yu-Liang
-
p. 1039 - 1042
(2013/05/08)
-
- INHIBITORS OF STEAROYL-COA DESATURASE
-
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
- -
-
-
- TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES
-
treatment of a variety of disorders, including the treatment of pathological conditions associated with tumor necrosis factor alpha. The inhibitors of tumor necrosis factor alpha have the following structures: including stereoisomers, pharmaceutically acceptable salts, and solvates thereof, wherein substituents are as defined herein. Compositions containing an inhibitor of tumor necrosis factor alpha in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
- -
-
Page/Page column 43
(2008/12/06)
-
- Neuroprotective small organic molecules, compositions and uses related thereto
-
The present application is directed to therapeutic compounds, compositions, and methods for culturing neuronal cells and for preventing and the treatment of neurodegenerative diseases, such as Parkinson's disease and amyotrophic lateral sclerosis (ALS).
- -
-
Page/Page column sheet 2; 44-45
(2008/06/13)
-
- Synthesis and biological evaluation of anthranilamide-based non-peptide mimetics of ω-conotoxin GVIA
-
Non-peptide mimetics based on an anthranilamide 'scaffold' possessing fragments that mimic Lys2, Tyr13 and Arg17 in ω-conotoxin GVIA have been prepared. Compounds were assayed for binding to the voltage-gated calcium channels Cav2.2 ('N-type')
- Baell, Jonathan B.,Duggan, Peter J.,Forsyth, Stewart A.,Lewis, Richard J.,Lok, Y. Phei,Schroeder, Christina I.,Shepherd, Nicholas E.
-
p. 7284 - 7292
(2007/10/03)
-
- 2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS
-
The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.
- -
-
Page/Page column 41
(2010/11/23)
-
- INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
-
Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures (Ia), (Ib) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
- -
-
-
- 2-ureido-benzamide derivatives
-
This invention is concerned with 2-ureido-benzamide compounds of the formula (1) STR1 in which R1 is H, halogen atom, (C1 -C4)alkyl, (C1 -C4)alkoxy or (C1 -C4)dialkylamino and R2 is H, halogen atom, hydroxy, nitro, (C1 -C4)alkyl, (C1 -C4)alkoxy, (C3 -C6) cycloalkylmethoxy, (C1 -C4) alkylthio, (C1 -C4) alkylsulfinyl, (C1 -C4)alkylsulfonyl or STR2 wherein j is an integer of from 0 to 2 and R3 and R4 are each independently H, (C1 -C4)alkyl, (C1 -C4)alkanoyl, (C1 -C4)alkylsulfonyl or (C1 -C4)alkylcarbamoyl, NR3 R4 can to form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring; X is a (C3 -C15)alkyl, (C3 -C6) cycloalkyl, (C3 -C6) cycloalkylmethyl, ω-(C1 -C4) alkoxy-(C1 -C4) alkyl group or STR3 wherein k is an integer of from 1 to 4 and R5 and R6 are each independently H, Y is H or (C1 -C4)alkyl and Z is STR4 wherein m is an integer of from 0 to 4.
- -
-
-
- Process for producing ortho-nitro aromatic acids by oxidation of ortho-nitroalkylaromatic compounds
-
A process for preparing o-nitroaromatic acids by direct oxidation of the corresponding o-nitroalkylaromatic compounds, utilizing salts of certain catalytic metals in the presence of an oxygen-containing gas and an aliphatic aldehyde or ketone at elevated temperature and pressure, is provided. The process allows catalyst recovery and reuse.
- -
-
-
- Amino-benzoic acids and derivatives, and methods of use
-
The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.
- -
-
-
- Pyrrolylbenzodiazepinones and medicines containing them
-
The present invention relates to compounds of the formula wherein R is methyl, fluorine or bromine,and pharmaceutically acceptable salts thereof. Utilizable as therapeutically active agents especially for the treatment of retroviral infections, particularly HIV infections, they can be prepared in a manner known per se by a process which comprises reacting 2-bromo-2'-(1H-pyrrol-2-yl-carbonyl)acetanilide, correspondingly substituted by R in the 4'-position, with ammonia and cyclizing the obtained 2-aminoacetanilide with pivalic acid.
- -
-
-
- SYNTHESIS AND DNA CROSSLINKING ABILITY OF A DIMERIC ANTHRAMYCIN ANALOG
-
Linked analogs of the DNA binding antibiotic anthramycin are made via nucleophilic aromatic substitution followed by reduction-cyclization.The linked compounds protect DNA from restriction endonucleases and reversibly crosslink DNA.
- Farmer, J.Dean,Rudnicki, Suzanne M.,Suggs, J.William
-
p. 5105 - 5108
(2007/10/02)
-